恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600276 恒瑞医药

已收盘 01-09 15:00:00

{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":63.78,"timestamp":1767942000000,"preClose":63.6,"halted":0,"volume":42635753,"delay":0,"changeRate":0.0028,"floatShares":6379000000,"shares":6637000000,"eps":1.1252,"marketStatus":"已收盘","change":0.18,"latestTime":"01-09 15:00:00","open":63.58,"high":64.2,"low":62.8,"amount":2710000000,"amplitude":0.022,"askPrice":63.79,"askSize":270,"bidPrice":63.78,"bidSize":316,"shortable":0,"etf":0,"ttmEps":1.1252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":63.6,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":69.96,"lowLimit":57.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":7.11,"roa":"--","peRate":56.683256,"roe":"11.09%","epsLYR":1,"committee":-0.158059,"marketValue":423321000000,"turnoverRate":0.0067,"status":0,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":76.75,"timestamp":1767946115005,"preClose":77.55,"halted":0,"volume":1385713,"delay":0,"premium":"+7.70"},"floatMarketCap":406853000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2602383553","title":"恒瑞医药获小摩增持约112.78万股 每股作价约74.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602383553","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602383553?lang=zh_cn&edition=full","pubTime":"2026-01-11 16:24","pubTimestamp":1768119840,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，1月6日，小摩增持恒瑞医药（01276）112.7828万股，每股作价74.6126港元，总金额约为8415.02万港元。增持后最新持股数目约为1919.4万股，最新持股比例为7.43%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-01-11/doc-inhfxmcp3824639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0820561818.USD","LU2237443622.USD","LU0417517546.SGD","LU2097828714.EUR","01276","IE00BJLML261.HKD","LU0203345920.USD","LU0820562030.AUD","LU0251132253.USD","LU1162221912.USD","LU2430703095.HKD","LU0820561909.HKD","LU1668664300.SGD","LU2237443549.SGD","LU1064131342.USD","LU0211328371.USD","LU0345769631.USD","LU0323591593.USD","IE00BLSP4452.SGD","BK0183","LU2211815571.USD","IE00BBT3K403.USD","LU1244550577.SGD","LU0787776722.HKD","IE00BN8TJ469.HKD","LU0070302665.USD","BK0188","IE000M9KFDE8.USD","LU2552382058.USD","LU2456880835.USD","LU1894683264.USD","BK4516","LU2417539215.USD","LU0238689110.USD","LU2097828805.USD","BK0196","IE00BHPRN162.USD","LU0320765489.SGD","LU2097828631.EUR","LU0256863811.USD","LU0265550359.USD","LU2580892862.HKD","IE00B1BXHZ80.USD","LU2552382132.HKD","LU2213496289.HKD","LU2505996681.GBP","LU1894683348.USD","600276","LU0106831901.USD","LU0868494708.USD"],"gpt_icon":0},{"id":"2602375349","title":"恒瑞医药：卡瑞利珠单抗在美国的BLA重新上市申报公司正在与FDA积极沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375349","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602375349?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:33","pubTimestamp":1767962029,"startTime":"0","endTime":"0","summary":"证券日报网讯1月9日，恒瑞医药在互动平台回答投资者提问时表示，卡瑞利珠单抗在美国的BLA重新上市申报公司正在与FDA积极沟通，相关事项如有进展公司将严格按照相关规定进行公告，履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601093614449751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","LU0405327494.USD","LU2097828714.EUR","LU1997244956.HKD","600276","LU0359201612.USD","LU1969619763.USD","LU1255011170.USD","LU1781817850.SGD","BK0239","LU2097828805.USD","LU1997245094.SGD","LU2097828557.USD","LU2328871848.SGD","LU2148510915.USD","LU1064130708.USD","LU2580892862.HKD","LU2488822045.USD","LU2495084118.USD","LU2580892789.USD","LU2097828631.EUR","BK0012","LU1023057109.AUD","LU1146622755.USD","LU2543165471.USD","BK0188","LU1820825898.SGD","LU1580142542.USD","BK0183","LU2289578879.USD","BK0028","01276","LU1655091616.SGD","LU1328615791.USD","LU0359202008.SGD","LU1997245177.USD","LU2097828474.EUR","BK0060","LU0359201885.HKD","LU0405327148.USD","BK0196","BK1191"],"gpt_icon":0},{"id":"2602378049","title":"恒瑞医药：公司前瞻性地广泛布局多个治疗领域，并向纵深发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2602378049","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602378049?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:05","pubTimestamp":1767960346,"startTime":"0","endTime":"0","summary":"证券日报网讯1月9日，恒瑞医药在互动平台回答投资者提问时表示，公司前瞻性地广泛布局多个治疗领域，并向纵深发展。公司在肿瘤领域有丰富的研发管线，与此同时，在代谢和心血管疾病、免疫和呼吸系统疾病、神经科学等领域也进行了广泛布局，打造长期发展的多元化战略支柱。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601093614409744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","LU1064130708.USD","BK0183","LU2148510915.USD","BK0028","LU1655091616.SGD","BK1191","LU2580892862.HKD","600276","01276","LU0359202008.SGD","LU2488822045.USD","LU1023057109.AUD","LU0359201885.HKD","LU2289578879.USD","LU1781817850.SGD","LU0405327494.USD","LU2495084118.USD","BK0188","BK0012","LU1820825898.SGD","LU1580142542.USD","LU2328871848.SGD","LU2097828805.USD","LU2097828631.EUR","LU2097828474.EUR","LU2543165471.USD","LU2097828557.USD","LU1146622755.USD","LU2580892789.USD","LU1328615791.USD","LU1997245177.USD","LU1255011170.USD","LU1997245094.SGD","BK0239","BK0196","LU2097828714.EUR","LU1969619763.USD","LU1997244956.HKD","LU1064131003.USD","LU0359201612.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"2602547378","title":"小摩增持恒瑞医药(01276)约112.78万股 每股作价约74.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602547378","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602547378?lang=zh_cn&edition=full","pubTime":"2026-01-09 19:29","pubTimestamp":1767958148,"startTime":"0","endTime":"0","summary":"1月6日，小摩增持恒瑞医药(01276)112.7828万股，每股作价74.6126港元，总金额约为8415.02万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260109/20260109193002_54761.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260109/20260109193002_54761.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0820561818.USD","BK0012","LU1116320737.USD","LU1997244956.HKD","IE00BLSP4452.SGD","BK4550","IE00BKVL7J92.USD","LU2357305700.SGD","LU2264538146.SGD","LU1146622755.USD","LU0405327148.USD","01276","LU1255011170.USD","LU2242649171.HKD","LU1720051017.SGD","LU1720051108.HKD","IE00BDRTCR15.USD","LU0640476718.USD","LU0256863811.USD","IE0034235295.USD","LU1668664300.SGD","LU2237443549.SGD","LU1548497426.USD","LU1119994496.HKD","LU1974910355.USD","LU0215105999.USD","LU2023250330.USD","LU2097828805.USD","LU1145028129.USD","LU1551013342.USD","LU2756315664.SGD","LU1328615791.USD","LU0689472784.USD","LU1084165304.USD","LU1244550494.USD","LU1267930490.SGD","LU2580892789.USD","BK0196","BK4533","IE00BLSP4239.USD","LU0234572021.USD","LU0417517546.SGD","LU1064131342.USD","IE00BJTD4V19.USD","LU2552382215.SGD","LU1894683264.USD","600276","LU2746668461.USD","LU0971096721.USD","LU0323591593.USD"],"gpt_icon":0},{"id":"2602429324","title":"“年度最受关注IPO公司”榜单出炉，宁德时代、地平线等领军新经济板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2602429324","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602429324?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:45","pubTimestamp":1767951913,"startTime":"0","endTime":"0","summary":"2025香港财富管理高峰论坛暨第十二届港股100强颁奖盛典正在隆重举行，各项榜单陆续揭晓。“年度最受关注IPO公司”榜单已揭晓。宁德时代（03750.HK）、美的集团（00300.HK）、恒瑞医药（01276.HK）、紫金黄金国际（02259.HK）、海天味业（03288.HK）等各领域领军企业集体入选。该榜单囊括新能源、智能制造、生物医药、新消费及人工智能等多元赛道，展现出资本市场对新经济企业的强烈关注。这些新上市企业凭借创新动能与成长潜力，正共同塑造港股市场的新格局，为投资者提供把握未来趋势的重要参考。作者|毛婷编辑|Danna","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109175936a4afd9b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109175936a4afd9b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1008478684.HKD","300750","02259","BK1610","01276","LU0067412154.USD","LU1960683339.HKD","LU1152091754.HKD","LU0880133367.SGD","00300","LU1152091168.USD","03288","LU1993786604.SGD","LU1807302812.USD","03750","BK1116","600276","603288","000333"],"gpt_icon":0},{"id":"2602326203","title":"恒瑞医药：注射用SHR-4394获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2602326203","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602326203?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:09","pubTimestamp":1767949759,"startTime":"0","endTime":"0","summary":"21智讯1月9日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意注射用SHR-4394开展临床试验。审批结论显示，该药物符合药品注册相关要求，同意开展SHR-4394或HRS-5041联合抗肿瘤治疗在前列腺癌参与者中的安全性、耐受性及有效性的多中心、开放II期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601093614272360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0405327148.USD","LU1064131003.USD","LU2488822045.USD","LU2097828805.USD","LU1655091616.SGD","LU2097828631.EUR","LU0359202008.SGD","BK0196","BK0060","LU1969619763.USD","LU2097828714.EUR","LU2495084118.USD","01276","LU1997244956.HKD","BK0012","BK1191","LU1023057109.AUD","LU2580892789.USD","LU2580892862.HKD","LU1580142542.USD","LU2097828474.EUR","LU0359201612.USD","BK0183","BK0239","LU1781817850.SGD","LU2148510915.USD","LU0405327494.USD","LU1820825898.SGD","LU2328871848.SGD","600276","LU1146622755.USD","LU1997245094.SGD","LU1997245177.USD","LU1328615791.USD","LU2543165471.USD","LU1255011170.USD","LU2097828557.USD","LU2289578879.USD","BK0028","LU1064130708.USD","BK0188","LU0359201885.HKD"],"gpt_icon":0},{"id":"2602332362","title":"智通AH统计|1月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2602332362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602332362?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:15","pubTimestamp":1767946505,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止1月9日收盘，东北电气、浙江世宝、南京熊猫电子股份分列AH溢价率前三位，溢价率分别为785.25%、448.59%、286.79%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-10.95%、-1.58%、-0.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0455707207.USD","LU0164880469.USD","LU1242518857.USD","BK1171","BK1562","HK0000320223.HKD","LU0516423091.SGD","SG9999001069.SGD","LU0501845795.SGD","HK0000165453.HKD","LU0072913022.USD","300750","LU0164865239.USD","LU0862451753.SGD","BK1191","LU0456827905.SGD","600276","BK1592","LU0370786039.SGD","LU1282649067.USD","LU1993786604.SGD","SG9999002950.SGD","BK1214","SG9999012744.USD","601995","SG9999006597.SGD","LU0051755006.USD","LU0516422366.SGD","LU0140636845.USD","BK1148","LU0589944569.HKD","IE00B543WZ88.USD","SG9999012736.USD","LU0463099449.HKD","LU0052750758.USD","LU2125910500.SGD","IE00BZ08YT58.USD","LU0228367735.SGD","LU2242644610.SGD","600036","BK1144","LU0329678170.USD","LU0561508036.HKD","LU1211504680.USD","LU2097828557.USD","SG9999014674.SGD","BK1205","LU0886674414.USD","LU0320764599.SGD","LU0061477393.USD","BK1522","LU0868486357.SGD","BK1558","LU0488056044.USD","SG9999001051.SGD","BK1184","LU0417516902.SGD","LU0348816934.USD","LU0737861772.HKD","LU0880133367.SGD","BK1116","BK1560","LU0972618739.USD","LU1769817096.USD","LU2045819591.USD","BK1501","LU0828237940.HKD","LU1282649141.HKD","LU1770034418.SGD","159982","03143","LU0359201612.USD","LU1960683339.HKD","LU0287142896.SGD","BK1564","LU1303224171.USD","BK1170","LU0348814723.USD","LU2476274308.USD","HK0000306701.USD","LU0588546209.SGD","LU0211977185.USD","LU1808992512.USD","IE00BF5LJ272.USD","BK1544","LU2476274720.SGD","IE00B5MMRT66.SGD","BK1110","LU1152091168.USD","LU1880383440.USD","BK1584","BK1505","LU0890818403.SGD","LU0348827113.USD","LU1023057109.AUD","BK1526","BK1550","BK1565","LU1282649810.SGD","002202","LU1152091754.HKD","BK1583","LU0516422952.EUR","LU2097828805.USD","LU1807302812.USD","LU2097828474.EUR","SG9999002463.SGD","BK1237","LU0456854461.SGD","LU0231483743.USD","399300","LU0039217434.USD","BK1576","LU0918141705.HKD","LU1224709979.USD","LU1785774172.SGD","LU0828237510.HKD","00042","BK1509","LU1831875114.USD","LU0791591158.USD","BK1516","BK1147","600775","LU1719994722.HKD","LU1008478684.HKD","LU2097828714.EUR","LU0502904849.HKD","01057","LU1720050803.USD","LU0106959298.USD","LU0096374516.USD","LU1688375341.USD","BK1183","SG9999012710.SGD","LU1046422090.SGD","LU0348735423.USD","LU1813983027.USD","LU0067412154.USD","LU0228659784.USD","LU0269904917.USD","LU0543330566.HKD","03968","BK1141","LU0345780281.USD","BK1198","LU0315179316.USD","LU1655091616.SGD","LU0572944931.SGD","IE00B031HY20.USD","LU0049853897.USD","03908","LU0640798160.USD","LU2039709279.SGD","SG9999001093.SGD","BK1546","BK1202","BK1223","LU0431992006.USD","BK1163","LU0918141887.USD","LU0181495838.USD","LU0648948544.HKD","LU1226287529.USD","LU0359201885.HKD","IE00B3M56506.USD","BK1149","LU1961090484.USD","LU2778985437.USD","BK1507","BK1514","LU1251922891.USD","LU0531971595.HKD","LU1794554557.SGD","LU0979878070.USD","LU0048580855.USD","LU0821914370.USD","LU2226246903.HKD","03750","LU0708995583.HKD","LU1880383366.USD","LU1048596156.SGD","LU2543165471.USD","LU0384037296.USD","LU0229945570.USD","LU1366334578.USD","LU0797268264.HKD","LU1105468828.SGD","000488","BK1554","LU0266512127.USD","LU1328277881.USD","00553","LU0117841782.USD","SG9999002828.SGD","LU0871576103.HKD","LU1366334651.USD","LU0326950275.SGD","LU0173614495.USD","LU0509642566.USD","CIHKY","LU0348788117.USD","BK1551","LU0327786744.USD","LU0516422440.USD","LU0163747925.USD","LU1188198961.HKD","BK1594","LU0244354667.USD","LU1504937902.USD","IE00BZ08YS42.EUR","LU1242518931.SGD","LU2399975544.HKD","LU0307460666.USD","IE00BVYPNQ40.USD","BK1231","LU0469268626.HKD","IE00B0169L03.USD","LU0593848301.USD","002703","IE00B031J352.USD","LU0328353924.USD","LU0348805143.USD","LU0737861699.HKD","01276","LU0359202008.SGD","LU0823426308.USD","BK1137","SG9999012728.SGD","BK1521","01812","SG9999004220.SGD","LU0149721374.USD","LU0634319403.HKD","LU0828238088.HKD","HK0000320264.USD","LU0314109678.HKD","HK0000306685.HKD","BK1513","IE00BVYPNP33.GBP","SG9999003461.SGD","LU2097828631.EUR","BK1221","IE0008369823.USD","IE00BYV24P56.USD","IE00BZ08YR35.GBP","LU1675838814.USD","LU0516423174.USD","IE00B29SXG58.USD","LU0823426480.USD","LU1115378108.SGD","LU1282648689.USD","IE0031814852.USD","SGXZ90724238.SGD","IE0034224299.USD","LU0348825331.USD","LU0417516738.SGD","LU0540923850.HKD","IE00BGHQDM52.EUR","LU1769817179.HKD","LU0266512473.USD","LU0345780521.USD","LU0791590937.USD","LU0329678337.USD","LU1481107354.HKD","LU0456846285.SGD","LU0106252389.USD","BK1610","IE0008368742.USD","IE00BMCWC346.EUR","IE0032431581.USD"],"gpt_icon":1},{"id":"2601533894","title":"宜明昂科与Axion“分手”；江西省卫健委党组书记被查","url":"https://stock-news.laohu8.com/highlight/detail?id=2601533894","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601533894?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:41","pubTimestamp":1767832919,"startTime":"0","endTime":"0","summary":"政策动向国家药监局：优化临床急需境外已上市药品审评审批央视新闻消息显示，为加快临床急需境外已上市药品在境内上市，满足患者临床用药迫切需求，国家药监局进一步优化这类药品审评审批。国家药监局表示，坚持以临床价值为导向，鼓励申请人在中国开展全球同步研发、同步申报上市；鼓励临床急需境外已上市的原研药及仿制药在境内申报，对于符合要求的可纳入优先审评审批范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601083612141760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601083612141760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828631.EUR","LU1064131003.USD","688321","LU2097828557.USD","LU2488822045.USD","BK0251","LU2097828474.EUR","LU2580892789.USD","LU1997245094.SGD","LU2097828805.USD","LU1997245177.USD","LU2580892862.HKD","300653","LU1064130708.USD","002173","LU2148510915.USD","LU2289578879.USD","LU2328871848.SGD","BK0114","BK0196","BK0239","BK0028","BK0236","LU1580142542.USD","LU0405327148.USD","LU1997244956.HKD","BK0060","LU1655091616.SGD","LU1781817850.SGD","LU1969619763.USD","LU1820825898.SGD","BK0077","LU2097828714.EUR","600276","688759","LU1328615791.USD","BK0046","LU1146622755.USD","BK0183","BK0188","LU0405327494.USD","LU2495084118.USD","LU1255011170.USD","BK0012","BK0096"],"gpt_icon":0},{"id":"2601871257","title":"恒瑞医药：瑞拉芙普α注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601871257","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601871257?lang=zh_cn&edition=full","pubTime":"2026-01-07 18:24","pubTimestamp":1767781450,"startTime":"0","endTime":"0","summary":"人民财讯1月7日电，恒瑞医药(600276)1月7日公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药监局的通知，批准公司自主研发的1类创新药瑞拉芙普α注射液上市。该药品联合氟尿嘧啶类和铂类药物用于经充分验证的检测评估PD-L1阳性（CPS≥1）的局部晚期不可切除、复发或转移性胃及胃食管结合部腺癌的一线治疗。经查询，国内外尚无同类产品获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611587624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","LU2580892862.HKD","LU2097828631.EUR","LU2289578879.USD","LU2097828557.USD","LU0359202008.SGD","LU1969619763.USD","LU1580142542.USD","LU1328615791.USD","LU2328871848.SGD","LU1064131003.USD","LU0405327494.USD","LU0405327148.USD","BK1191","LU2488822045.USD","BK0028","LU1997245177.USD","01276","LU1064130708.USD","LU1997244956.HKD","LU2097828474.EUR","LU1655091616.SGD","LU2148510915.USD","BK0188","LU0359201612.USD","BK0060","LU0359201885.HKD","LU1255011170.USD","LU2495084118.USD","LU1997245094.SGD","LU2097828714.EUR","LU2543165471.USD","600276","LU1781817850.SGD","LU1023057109.AUD","LU1146622755.USD","LU2580892789.USD","LU1820825898.SGD","LU2097828805.USD","BK0012","BK0239","BK0196"],"gpt_icon":0},{"id":"2601685608","title":"恒瑞医药2025年12月股份变动：A股员工持股计划致总股本微增","url":"https://stock-news.laohu8.com/highlight/detail?id=2601685608","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601685608?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:52","pubTimestamp":1767671537,"startTime":"0","endTime":"0","summary":"中访网数据 江苏恒瑞医药股份有限公司于2026年1月5日发布了截至2025年12月31日的证券变动月报表。报告显示，公司总股本在报告期内略有增加。此次A股股份的增加，源于公司根据其2022年、2023年、2024年及2025年A股员工持股计划进行的股份授予或归属，本月内因此新增发行了3,738,950股A股。本次变动后，江苏恒瑞医药的总已发行股份数达到6,637,199,874股。公司库存股份数量在本月内未发生变动，A股和H股的库存股份数均为零。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260106/31918645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU0405327148.USD","LU1064131003.USD","LU2488822045.USD","LU2097828805.USD","LU1655091616.SGD","399300","LU2097828631.EUR","LU0359202008.SGD","BK0196","BK0060","LU1969619763.USD","LU2097828714.EUR","LU2495084118.USD","01276","LU1997244956.HKD","BK0012","BK1191","LU1023057109.AUD","LU2580892789.USD","LU2580892862.HKD","LU1580142542.USD","LU2097828474.EUR","LU0359201612.USD","BK0183","BK0239","LU1781817850.SGD","LU2148510915.USD","LU0405327494.USD","LU1820825898.SGD","LU2328871848.SGD","600276","LU1146622755.USD","LU1997245094.SGD","LU1997245177.USD","LU1328615791.USD","LU2543165471.USD","LU1255011170.USD","LU2097828557.USD","LU2289578879.USD","BK0028","LU1064130708.USD","BK0188","159982","LU0359201885.HKD"],"gpt_icon":0},{"id":"2601004192","title":"恒瑞医药：子公司收到药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2601004192","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601004192?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:09","pubTimestamp":1767604169,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月5日，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的关于HRS-4357注射液、HRS-5041片的《药物临床试验批准通知书》，同意开展临床试验。具体为：HRS-4357联合HRS-5041用于PSMA阳性前列腺癌治疗的安全性、耐受性及初步疗效的开放、多中心、Ib/II期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601053608869671.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608869671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","BK0060","BK0183","LU1997244956.HKD","LU2097828474.EUR","LU2097828714.EUR","LU2543165471.USD","600276","LU2328871848.SGD","LU1146622755.USD","LU1820825898.SGD","LU2097828631.EUR","LU1997245177.USD","BK0012","01276","BK0239","LU1023057109.AUD","LU1655091616.SGD","LU0405327148.USD","BK0028","LU1064130708.USD","LU2488822045.USD","LU1969619763.USD","LU1328615791.USD","LU0359202008.SGD","BK1191","LU0359201885.HKD","LU1064131003.USD","LU2289578879.USD","LU0359201612.USD","LU2580892789.USD","BK0196","LU2580892862.HKD","LU0405327494.USD","LU1997245094.SGD","BK0188","LU1580142542.USD","LU2097828557.USD","LU2495084118.USD","LU1781817850.SGD","LU2097828805.USD","LU1255011170.USD"],"gpt_icon":0},{"id":"2600152047","title":"恒瑞医药(01276)截至12月末累计回购A股股份889.87万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2600152047","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600152047?lang=zh_cn&edition=full","pubTime":"2026-01-04 18:48","pubTimestamp":1767523708,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，2025年12月，公司通过上海证券交易所交易系统以集中竞价交易方式回购股份0股。截至2025年12月31日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份889.87万股，已回购股份占公司总股本的比例为0.13%，购买的最高价为人民币70.00元/股，最低价为人民币59.32元/股，已支付的总金额为人民币59,521.63万元(不含交易费用)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","LU1064131003.USD","BK1191","LU1820825898.SGD","LU1781817850.SGD","LU2580892789.USD","LU1580142542.USD","LU1997245177.USD","LU2097828714.EUR","LU2097828557.USD","BK0239","LU2580892862.HKD","LU1997245094.SGD","600276","LU0405327494.USD","LU2097828474.EUR","LU2289578879.USD","159982","LU0359201885.HKD","399300","01276","LU2488822045.USD","LU1023057109.AUD","LU0359202008.SGD","BK0196","BK0060","BK0012","BK0028","LU1655091616.SGD","LU2097828805.USD","LU1328615791.USD","LU2148510915.USD","LU1064130708.USD","LU1255011170.USD","LU0405327148.USD","LU1969619763.USD","LU1997244956.HKD","LU2097828631.EUR","BK0188","LU2328871848.SGD","LU2543165471.USD","LU1146622755.USD","LU2495084118.USD","BK0183"],"gpt_icon":0},{"id":"2600054319","title":"智通AH统计|1月2日","url":"https://stock-news.laohu8.com/highlight/detail?id=2600054319","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600054319?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:15","pubTimestamp":1767341704,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止1月2日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为847.37%、398.38%、286.02%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-14.50%、-5.83%、-3.71%。其中浙江世宝、广和通、中船防务的偏离值位居前三，分别为86.11%、17.07%、11.89%；另外，东北电气、新华保险、广汽集团的偏离值位居后三，分别为-40.60%、-13.42%、-13.31%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1558","BK1183","BK1544","399300","IE0031814852.USD","LU0214875030.USD","LU0572939691.SGD","LU1366334578.USD","LU2543165471.USD","01057","LU0327786744.USD","LU0918141705.HKD","LU0140636845.USD","LU2242644610.SGD","BK1129","LU2778985437.USD","300750","LU0828237510.HKD","LU0871576103.HKD","LU0431992006.USD","LU0540923850.HKD","LU0648948544.HKD","LU1251922891.USD","LU1282649067.USD","LU0862451753.SGD","LU0516422440.USD","LU1242518931.SGD","00042","LU0797268264.HKD","LU0228367735.SGD","LU1366334651.USD","LU2399975544.HKD","LU1481107354.HKD","HK0000500386.USD","LU0469268626.HKD","LU0359201885.HKD","LU0348805143.USD","IE00B031J352.USD","LU0516422952.EUR","LU0828237940.HKD","SG9999014674.SGD","IE00BGHQDM52.EUR","LU1282648689.USD","BK1154","LU0823426480.USD","LU1961090484.USD","BK1614","LU0868486357.SGD","159982","BK1116","LU0039217434.USD","LU0244354667.USD","LU1769817096.USD","SG9999001226.SGD","LU0348816934.USD","LU1023057109.AUD","LU2097828474.EUR","LU1008478684.HKD","BK1202","LU0886674414.USD","LU0348825331.USD","LU2226246903.HKD","LU0326950275.SGD","BK1205","LU1769817179.HKD","BK1584","LU1831875114.USD","IE0034224299.USD","600276","LU0173614495.USD","IE00BZ08YT58.USD","LU0531970944.HKD","HK0000320264.USD","LU1993786604.SGD","LU0531971595.HKD","LU0572940350.SGD","LU0163747925.USD","BK1505","LU0348827113.USD","LU0348735423.USD","LU2097828714.EUR","LU0149721374.USD","LU0315179316.USD","LU0821914370.USD","LU2125910500.SGD","LU0708995583.HKD","03678","LU0516422366.SGD","BK1173","LU0456827905.SGD","LU0823040885.USD","BK1551","LU0561508036.HKD","IE00BYV24P56.USD","LU1303224171.USD","LU1813983027.USD","BK1576","LU0455707207.USD","LU0791590937.USD","LU1675838814.USD","BK1523","BK1610","600036","LU0061477393.USD","BK1546","HK0000306685.HKD","LU0791591158.USD","IE00B5MMRT66.SGD","LU0229945570.USD","IE00B29SXG58.USD","LU0880133367.SGD","BK1147","BK1526","IE00B543WZ88.USD","BK1594","BK1521","IE00BZ08YR35.GBP","LU0231483743.USD","LU0516423091.SGD","BK1149","LU0370786039.SGD","LU0417516902.SGD","LU0502904849.HKD","LU1960683339.HKD","LU2045819591.USD","LU1880383440.USD","LU2476274308.USD","LU1152091168.USD","BK1562","IE0008368742.USD","LU0501845795.SGD","LU0106252389.USD","SG9999006597.SGD","BK1105","HK0000306701.USD","LU0307460666.USD","LU0345780281.USD","LU0543330566.HKD","BK1191","BK1190","LU0456854461.SGD","LU0572944931.SGD","BK1119","LU0449509016.USD","LU1688375341.USD","LU0320764599.SGD","IE00B031HY20.USD","BK1535","LU0918141887.USD","LU1794554557.SGD","BK1509","LU0052750758.USD","LU0589944569.HKD","BK1515","IE00B0169L03.USD","03968","LU1105468828.SGD","LU0096374516.USD","BK1214","IE00BVYPNP33.GBP","BK1171","BK1560","LU0254981946.USD","LU0359201612.USD","BK1144","BK1231","BK1514","LU1328277881.USD","01276","IE00B3M56506.USD","LU0051755006.USD","BK1141","LU1224709979.USD","BK1554","LU0048580855.USD","LU1211504680.USD","BK1592","LU0164865239.USD","BK1237","LU2097828631.EUR","LU2039709279.SGD","LU0106959298.USD","LU1046422090.SGD","BK1163","LU1719994722.HKD","BK1583","LU0456846285.SGD","LU1048596156.SGD","001236","LU0359202008.SGD","03143","BK1198","BK1506","LU0067412154.USD","LU0329678337.USD","BK1607","LU0516423174.USD","HK0000252152.HKD","LU0117841782.USD","LU2097828805.USD","LU0211977185.USD","LU1282649141.HKD","SG9999004220.SGD","BK1179","LU0072913022.USD","LU1115378108.SGD","LU1808992512.USD","BK1124","SG9999003461.SGD","LU0979878070.USD","BK1539","LU1242518857.USD","LU1720050803.USD","HK0000320223.HKD","LU0640798160.USD","IE00BMCWC346.EUR","LU0588546209.SGD","LU0348788117.USD","LU0264606111.USD","LU1770034418.SGD","LU0164880469.USD","LU2476274720.SGD","BK1564","LU1226287529.USD","LU0328353924.USD","SG9999002828.SGD","BK1184","LU1152091754.HKD","LU1188198961.HKD","LU0417516738.SGD","LU0266512473.USD","HK0000252160.HKD","IE00BZ08YS42.EUR","LU0181495838.USD","IE00BF5LJ272.USD","BK1507","LU0314109678.HKD","LU0345780521.USD","LU0449515922.USD","LU0737861772.HKD","LU1504937902.USD","LU0266512127.USD","LU0348814723.USD","LU0228659784.USD","LU0463099449.HKD","LU0823426308.USD","BK1522","LU0049853897.USD","IE00BVYPNQ40.USD","LU0054450605.USD","LU0329678170.USD","002703","LU0384037296.USD","CIHKY","BK1223","LU0593848301.USD","LU0890818403.SGD","SG9999002463.SGD","BK1550","LU1880383366.USD","LU1282649810.SGD","LU0634319403.HKD","LU0737861699.HKD","LU1807302812.USD","LU2097828557.USD","LU0287142896.SGD","IE0008369823.USD","LU0488056044.USD"],"gpt_icon":1},{"id":"2600056352","title":"港股异动 | 恒瑞医药(01276)午后涨超5% CLDN18.2 ADC胃癌适应症纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2600056352","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600056352?lang=zh_cn&edition=full","pubTime":"2026-01-02 13:43","pubTimestamp":1767332632,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药午后涨超5%，截至发稿，涨5.19%，报74.95港元，成交额5568.71万港元。消息面上，恒瑞医药宣布，其自主研发的靶向Claudin18.2的抗体药物偶联物——注射用SHR-A1904，已被国家药品监督管理局药品审评中心正式纳入突破性治疗品种名单。该药物拟用于治疗既往接受过至少一线系统治疗的CLDN18.2阳性的局部晚期或转移性胃或胃食管交界处腺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1146622755.USD","LU1820825898.SGD","LU0405327494.USD","BK0060","BK0188","LU2097828474.EUR","LU2543165471.USD","LU1255011170.USD","LU1064131003.USD","LU2289578879.USD","BK0196","LU1781817850.SGD","LU0359201885.HKD","LU2097828714.EUR","LU0359202008.SGD","01276","LU2328871848.SGD","LU0405327148.USD","LU2580892862.HKD","LU2097828805.USD","BK0183","BK4080","LU0359201612.USD","LU2495084118.USD","LU1969619763.USD","BK4231","BK0028","LU2097828631.EUR","BK0239","BK0012","LU1023057109.AUD","BK1191","LU2097828557.USD","LU1997245177.USD","LU1064130708.USD","LU1997244956.HKD","LU1997245094.SGD","LU1580142542.USD","LU1655091616.SGD","LU2148510915.USD","600276","LU2488822045.USD","ADC","LU1328615791.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2595792596","title":"恒瑞医药六款创新药获临床试验批件，肿瘤管线再扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2595792596","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595792596?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:26","pubTimestamp":1767097566,"startTime":"0","endTime":"0","summary":"中访网数据 江苏恒瑞医药股份有限公司及其子公司近日宣布，其自主研发及引进的六款抗肿瘤新药已获得国家药品监督管理局颁发的药物临床试验批准通知书，即将进入临床研究阶段。此次获批的药品包括SHR-4375注射液、阿得贝利单抗注射液、SHR-8068注射液、贝伐珠单抗注射液、HRS-4642注射液及注射用SHR-9839，将联合开展一项针对晚期实体肿瘤患者的Ib/II期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31904557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","BK0188","LU1328615791.USD","LU0405327148.USD","LU2495084118.USD","LU2488822045.USD","LU1146622755.USD","LU1969619763.USD","LU1997245094.SGD","LU2580892789.USD","LU2097828714.EUR","LU1997244956.HKD","LU0359202008.SGD","LU2543165471.USD","159992","BK0239","LU1781817850.SGD","LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","BK0196","LU2580892862.HKD","BK1191","LU1997245177.USD","LU1820825898.SGD","BK1574","LU0359201612.USD","BK0183","01276","LU2097828805.USD","LU0405327494.USD","LU1655091616.SGD","LU2097828474.EUR","LU2328871848.SGD","BK0060","LU1255011170.USD","BK0012","LU1023057109.AUD","LU2097828557.USD","LU2097828631.EUR","LU2289578879.USD","600276","LU0359201885.HKD","BK1161","06978","LU1580142542.USD"],"gpt_icon":0},{"id":"2595782399","title":"恒瑞医药SHR-4375注射液等6款药品临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2595782399","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595782399?lang=zh_cn&edition=full","pubTime":"2025-12-29 19:16","pubTimestamp":1767006961,"startTime":"0","endTime":"0","summary":"北京商报讯12月29日，恒瑞医药发布公告称，公司及子公司上海恒瑞医药有限公司、上海盛迪医药有限公司、苏州盛迪亚生物医药有限公司收到国家药品监督管理局核准签发关于SHR-4375注射液、阿得贝利单抗注射液、SHR-8068注射液、贝伐珠单抗注射液、HRS-4642注射液、注射用SHR-9839（sc）的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512293604578310.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604578310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","LU1064131003.USD","LU0359201612.USD","LU1064130708.USD","LU2289578879.USD","LU1781817850.SGD","BK0196","LU1255011170.USD","LU1580142542.USD","LU2495084118.USD","LU1997245094.SGD","BK1191","BK0028","BK0239","LU2148510915.USD","LU1328615791.USD","LU2543165471.USD","LU1655091616.SGD","LU0359201885.HKD","LU1023057109.AUD","BK0060","LU0405327494.USD","BK0188","LU2097828631.EUR","LU1997244956.HKD","LU1969619763.USD","LU2580892789.USD","BK0183","LU2097828474.EUR","BK0012","LU1820825898.SGD","LU0405327148.USD","LU2097828714.EUR","LU2097828557.USD","LU1997245177.USD","LU1146622755.USD","LU2097828805.USD","LU2580892862.HKD","LU2488822045.USD","01276","600276","LU0359202008.SGD"],"gpt_icon":0},{"id":"2595781654","title":"智通港股空仓持单统计|12月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2595781654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595781654?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:30","pubTimestamp":1767004204,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月19日，未平仓空单比位列前三位为万科企业、中远海控、恒瑞医药，空仓比分别为18.48%、16.79%、15.54%。未平仓空单比（绝对值）较上一次增加最多为宁德时代、蓝思科技、优必选，分别增加2.35%、2.34%、1.29%。智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；以上涉及的空仓比增加值或减少值为绝对值数。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0384037296.USD","LU1188198961.HKD","BK1505","BK1604","IE00BZ08YT58.USD","LU0370786039.SGD","LU0329678337.USD","BK1228","LU0072462343.USD","LU0359201612.USD","LU0054450605.USD","LU2045819591.USD","LU2242644610.SGD","82318","BK1147","BK1161","LU0348735423.USD","LU0880133367.SGD","BK1141","LU2293587155.HKD","LU0862451753.SGD","300433","LU1303224171.USD","LU0327786744.USD","LU1366334651.USD","LU0648948544.HKD","LU0348816934.USD","LU1522347837.USD","LU0469268626.HKD","01919","BK1191","BK1149","SG9999003461.SGD","BK1522","HK0000500386.USD","LU0819121731.USD","BK1618","LU1224709979.USD","300750","LU0211977185.USD","06613","LU0084288322.USD","LU0856984785.SGD","LU0588545730.USD","LU0196878994.USD","BK1095","LU0228367735.SGD","LU0348827113.USD","LU0605514214.HKD","BK1526","LU1282649141.HKD","600276","BK1610","BK1594","LU0049112450.USD","LU1282649067.USD","BK1546","LU0828237510.HKD","LU1720050803.USD","LU0043850808.USD","LU1044874839.SGD","BK1184","LU0140636845.USD","IE00BZ08YS42.EUR","LU0348767384.USD","LU0181495838.USD","LU0417516902.SGD","SG9999001093.SGD","BK1103","LU0823426480.USD","LU0348814723.USD","BK1170","IE00BZ08YR35.GBP","BK1544","BK1576","LU0456827905.SGD","BK1619","LU0197773160.USD","LU1051769294.HKD","LU0572944931.SGD","LU0865486749.SGD","LU0235996351.USD","LU1282649810.SGD","BK1564","LU2097828805.USD","LU0039217434.USD","LU0266512127.USD","LU0871576103.HKD","LU0061477393.USD","IE0034224299.USD","LU0052750758.USD","LU0326950275.SGD","LU1504937902.USD","LU0164872284.USD","LU2039709279.SGD","LU0630378692.HKD","LU0417516571.SGD","BK1563","LU2097828631.EUR","LU1769817096.USD","BK1595","LU1008478684.HKD","BK1589","LU1642822792.SGD","LU1048588211.SGD","601869","LU0106252389.USD","LU0244354667.USD","BK1592","IE00BF5LJ272.USD","LU0345780281.USD","80020","LU1981816686.USD","SG9999006597.SGD","BK1550","LU0791591158.USD","LU0878004406.USD","LU2543165471.USD","LU1282651048.USD","LU2778985437.USD","601318","01318","BK1501","LU0819123356.HKD","BK1535","LU0315178854.USD","BK1116","LU1497733557.USD","LU0882747503.HKD","LU1224444064.USD","LU1719994722.HKD","LU0359202008.SGD","LU0345780521.USD","LU0348788117.USD","LU0594300419.USD","LU1880383366.USD","LU0918141705.HKD","LU1226287529.USD","LU0634319403.HKD","LU1769817179.HKD","LU0540923850.HKD","LU0737861699.HKD","02202","LU0531971595.HKD","HK0000252160.HKD","IE0003895053.USD","LU1960683339.HKD","LU0049853897.USD","SG9999001440.SGD","LU2153592121.USD","LU0348805143.USD","LU1808992512.USD","LU1152091754.HKD","LU0878005551.USD","LU1481107354.HKD","BK1575","LU0254981946.USD","LU0918141887.USD","BK1607","LU0348783233.USD","LU1880383440.USD","PAImain","LU1152091168.USD","LU0314109678.HKD","LU0197773673.USD","LU1831875114.USD","LU0594300179.USD","LU0328353924.USD","000002","IE00BYV24P56.USD","BK1588","LU0287142896.SGD","LU0067412154.USD","LU0173614495.USD","HK0000306685.HKD","LU0307460666.USD","LU1282651121.HKD","BK1169","LU1813983027.USD","BK1612","LU0096374516.USD","HK0000320264.USD","LU0417516738.SGD","BK1555","LU2399975544.HKD","LU0456854461.SGD","LU0315179316.USD","LU1211504680.USD","LU0561508036.HKD","LU1634259557.SGD","LU1961090484.USD","BK1608","LU0797268264.HKD","LU0762540952.USD","LU0791590937.USD","LU0886674414.USD","LU0329678170.USD","LU0463099449.HKD","BK1587","LU0651947912.USD","LU2476274308.USD","LU0106959298.USD","LU1051768304.USD","LU0630378429.USD","BK1523","LU0828237940.HKD","LU0651946864.USD","LU0501845795.SGD","LU0831093199.SGD","LU2097828714.EUR","BK1507","LU1251922891.USD","LU2097828474.EUR","BK1168","LU0762542818.HKD","LU0165289439.USD","LU0348825331.USD","03145","LU0588545904.SGD","PNGAY","BK1198","LU0228659784.USD","BK1135","LU2125910500.SGD","SG9999002562.SGD","LU0890818403.SGD","BK1188","LU0588546209.SGD","BK1131","LU1046422090.SGD","SG9999001069.SGD","LU0163747925.USD","BK1521","BK1515","BK1196","BK1556","LU0320764599.SGD","LU2226246903.HKD","LU1328277881.USD","LU1115378108.SGD","LU0048580855.USD","LU0737861772.HKD","LU0762541174.USD","LU1235295612.USD","HK0000252152.HKD","BK1240","LU0348766576.USD","IE00BVYPNQ40.USD","LU1242518931.SGD","IE00BVYPNP33.GBP","LU1497734951.SGD","SG9999002828.SGD","LU2097828557.USD","LU0348783662.USD","LU1044876610.USD","LU0488056044.USD","01276","BK1183","LU1044875133.USD","LU0359201885.HKD","LU1807302812.USD","LU0051755006.USD","LU1515016050.SGD","LU2488822045.USD","601919","BK1207","LU0611395673.USD","BK1205","LU1366334578.USD","LU0640798160.USD","LU1675838814.USD","BK1506","LU0164880469.USD","LU1993786604.SGD","LU2476274720.SGD","LU0149721374.USD","BK1613","BK1516","LU0821914370.USD","00357","LU0588545490.SGD","LU1634259391.SGD","IE00BMCWC346.EUR","03750","BK1529","SG9999001051.SGD","BK1554","SG9999004311.SGD","LU1023057109.AUD","LU0979878070.USD","LU0072913022.USD","BK1615","LU1794554557.SGD","SG9999002463.SGD","LU1048596156.SGD","LU0266512473.USD","BK1503","LU0164865239.USD","IE00BGHQDM52.EUR","BK1504","BK1583","HK0000320223.HKD","LU1105468828.SGD","BK1109","SG9999014674.SGD","IE00B29SXG58.USD","LU0293314216.USD","LU0823426308.USD","LU1242518857.USD","LU0650527681.SGD","LU1770034418.SGD","BK1104","LU1282648689.USD","IE0008368742.USD","LU0348784397.USD","LU0708995583.HKD","LU2348774022.SGD","SG9999004220.SGD","BK1127","BK1561","LU1497733631.SGD","HPAD.SI","LU0449515922.USD","HK0000306701.USD"],"gpt_icon":1},{"id":"2594822143","title":"恒瑞医药(600276.SH)与翰森制药签署SHR6508项目独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2594822143","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594822143?lang=zh_cn&edition=full","pubTime":"2025-12-28 16:43","pubTimestamp":1766911410,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公告，公司与翰森制药集团有限公司签署《独家许可协议》，将公司SHR6508项目有偿许可给翰森制药;公司子公司成都盛迪医药有限公司与翰森制药子公司江苏豪森药业集团有限公司签署《商业化服务框架协议》，委托豪森药业为公司帕立骨化醇软胶囊产品提供非独家商业化服务。公司帕立骨化醇软胶囊于2025年11月获得国家药监局批准上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","LU1580142542.USD","LU1328615791.USD","BK0239","BK1583","LU1655091616.SGD","LU2097828714.EUR","LU1146622755.USD","LU1997244956.HKD","LU2097828631.EUR","LU1997245094.SGD","LU0405327494.USD","LU1781817850.SGD","LU1023057109.AUD","LU1064131003.USD","BK0196","LU2148510915.USD","LU2580892862.HKD","LU1064130708.USD","LU2289578879.USD","LU2097828474.EUR","LU1997245177.USD","LU2097828557.USD","LU2495084118.USD","BK0188","LU2488822045.USD","BK0060","LU0359201885.HKD","LU0405327148.USD","LU2580892789.USD","BK1191","BK0183","01276","LU2097828805.USD","LU2328871848.SGD","BK0028","600276","LU1969619763.USD","LU2543165471.USD","BK0012","LU1255011170.USD","LU1820825898.SGD","LU0359202008.SGD","LU0359201612.USD","BK1589"],"gpt_icon":0},{"id":"2594610296","title":"恒瑞医药：预计2026年3月26日公布年报，预测Q4一致预期营收320.72~360.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594610296","media":"朝阳永续","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594610296?lang=zh_cn&edition=full","pubTime":"2025-12-26 19:01","pubTimestamp":1766746860,"startTime":"0","endTime":"0","summary":"截至2025年12月26日，根据朝阳永续季度业绩前瞻数据：预测公司Q4一致预期营业收入320.72~360.62亿元，同比增长14.6%~28.9%；预测公司Q4一致预期净利润78.82~100.96亿元，同比增长24.4%~59.3%。在业务发展方面，恒瑞医药在对外授权合作上取得显著成果，与GSK、Glenmark和Braveheart_Bio等公司达成合作，涉及药物首付款总计5.83亿美元，里程碑付款最高可达141.16亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-26/doc-inhecrxk0904902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01276","600276"],"gpt_icon":0},{"id":"2594622922","title":"智通AH统计|12月26日","url":"https://stock-news.laohu8.com/highlight/detail?id=2594622922","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594622922?lang=zh_cn&edition=full","pubTime":"2025-12-26 16:15","pubTimestamp":1766736905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月26日收盘，东北电气、浙江世宝、钧达股份分列AH溢价率前三位，溢价率分别为900.00%、472.95%、286.59%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-11.39%、-3.20%、2.72%。其中浙江世宝、钧达股份、南京熊猫电子股份的偏离值位居前三，分别为187.01%、94.84%、36.09%；另外，广汽集团、长飞光纤光缆、北京北辰实业股份的偏离值位居后三，分别为-22.30%、-19.89%、-10.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0314109678.HKD","LU0264606111.USD","LU0163747925.USD","BK1223","BK1550","BK1535","BK1141","LU0593848301.USD","IE0034224299.USD","LU0737861699.HKD","IE00B5MMRT66.SGD","LU0348825331.USD","LU2778985437.USD","LU0326950275.SGD","LU0501845795.SGD","LU0164865239.USD","LU0229945570.USD","LU2476274308.USD","HK0000306685.HKD","LU1831875114.USD","LU0572939691.SGD","BK1509","LU1720050803.USD","IE00BZ18W340.USD","LU0414403682.SGD","BK1592","LU0516423174.USD","LU1504937902.USD","LU0572940350.SGD","LU1366334651.USD","LU0972618739.USD","LU1211504680.USD","LU0868486357.SGD","IE00BZ18W456.USD","00553","LU0345780281.USD","LU0918141705.HKD","601869","LU0054450605.USD","BK1523","LU0266512473.USD","LU1224709979.USD","LU1251922891.USD","LU1023057109.AUD","LU0543330566.HKD","BK1206","BK1214","601238","LU1770034418.SGD","LU2097828474.EUR","LU0516422440.USD","HK0000306701.USD","02238","BK1562","IE00BF5LJ272.USD","03968","BK1551","IE00B543WZ88.USD","03750","IE0031814852.USD","00042","LU0516423091.SGD","BK1237","BK1546","LU0516422366.SGD","002703","LU1282649067.USD","LU1880383440.USD","BK1544","BK1505","LU0979878070.USD","LU2543165471.USD","LU0106959298.USD","LU0589944569.HKD","LU1880383366.USD","IE00B031HY20.USD","BK1183","LU0648948544.HKD","LU1481107354.HKD","SG9999002950.SGD","BK1514","LU1655091616.SGD","LU1813983027.USD","00588","LU0405327494.USD","LU0348805143.USD","LU0738912210.USD","LU1719994722.HKD","LU0140636845.USD","LU0211977185.USD","03143","BK1558","LU1282649141.HKD","IE00BZ08YR35.GBP","BK1184","LU1808992512.USD","LU2039709279.SGD","LU0862451753.SGD","LU0214875030.USD","600775","LU2097828557.USD","LU2476274720.SGD","BK1539","LU0266512127.USD","BK1191","BK1521","LU1303224171.USD","BK1149","01057","LU0244354667.USD","LU0823426308.USD","LU0049853897.USD","LU0370786039.SGD","LU0405327148.USD","HK0000320223.HKD","LU0328353924.USD","LU0737861772.HKD","LU0890818403.SGD","LU0329678170.USD","BK1513","LU0509642566.USD","LU1960683339.HKD","LU2125910500.SGD","HK0000252160.HKD","LU0320764599.SGD","BK1205","LU0181495838.USD","LU0797268264.HKD","LU1366334578.USD","LU2097828631.EUR","BK1576","LU0287142896.SGD","BK1116","LU0345780521.USD","LU0823040885.USD","LU0327786744.USD","LU1226287529.USD","LU0634319403.HKD","601588","LU0173614495.USD","IE00BZ08YS42.EUR","LU0918141887.USD","LU0359201885.HKD","IE00BMQBXF63.USD","LU0828238088.HKD","LU0164880469.USD","LU0791590937.USD","LU0449515922.USD","LU0791591158.USD","IE0008368742.USD","LU0886674414.USD","BK1240","LU0149721374.USD","SG9999002828.SGD","LU0871576103.HKD","LU1046422090.SGD","LU0431992006.USD","CIHKY","BK1173","LU0231483743.USD","SG9999002463.SGD","IE0008369823.USD","LU1242518857.USD","LU1807302812.USD","LU0228367735.SGD","LU0052750758.USD","LU1794554557.SGD","LU0228659784.USD","LU0315179316.USD","LU0828237510.HKD","LU0269904917.USD","LU1188198961.HKD","LU1152091168.USD","LU0117841782.USD","LU1152091754.HKD","IE00B3M56506.USD","LU0531971595.HKD","LU0449509016.USD","LU2097828714.EUR","600276","HK0000320264.USD","SG9999014674.SGD","LU1282649810.SGD","BK1560","LU0572944931.SGD","BK1567","IE00BYV24P56.USD","LU1328277881.USD","LU1961090484.USD","LU0640798160.USD","HK0000252152.HKD","LU0348827113.USD","LU0456846285.SGD","BK1584","LU1993786604.SGD","BK1231","IE00BZ08YT58.USD","BK1144","LU1769817179.HKD","BK1119","LU2045819591.USD","LU0307460666.USD","LU2242644610.SGD","LU0348788117.USD","LU0488056044.USD","01276","LU0828237940.HKD","LU0051755006.USD","IE00B031J352.USD","LU1688375341.USD","LU0061477393.USD","LU0359201612.USD","LU0348814723.USD","LU0531970944.HKD","BK1554","LU0348816934.USD","IE00B0169L03.USD","LU0384037296.USD","LU1282648689.USD","SG9999004220.SGD","LU0039217434.USD","LU0456854461.SGD","LU0540923850.HKD","LU0708995583.HKD","IE00B29SXG58.USD","LU0561508036.HKD","LU0588546209.SGD","LU1769817096.USD","LU0456827905.SGD","LU2097828805.USD","LU0348735423.USD","LU0048580855.USD","LU1008478684.HKD","LU2399975544.HKD","BK1129","BK1163","300750","BK1583","BK1610","LU0417516902.SGD","LU0329678337.USD","BK1202","LU1048596156.SGD","LU0106252389.USD","LU1242518931.SGD","IE00BVYPNP33.GBP","BK1568","IE00BVYPNQ40.USD","BK1154","BK1507","LU2226246903.HKD","LU1785774172.SGD","LU1105468828.SGD","LU0880133367.SGD","LU0072913022.USD","LU0254981946.USD","LU0516422952.EUR","LU0096374516.USD","LU0067412154.USD","LU1675838814.USD","SG9999006597.SGD","02865","LU0469268626.HKD","BK1506","LU0359202008.SGD","BK1198","BK1185","BK1564","BK1594","LU0417516738.SGD","LU0455707207.USD","BK1171","LU0463099449.HKD","LU1115378108.SGD","BK1147","600036","LU0823426480.USD","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","LU0821914370.USD","BK1522","LU0502904849.HKD","HK0000500386.USD"],"gpt_icon":1}],"profile":{"ret":0,"serverTime":1768176923016,"stockEarnings":[{"period":"1week","weight":0.0707},{"period":"1month","weight":0.0063},{"period":"3month","weight":-0.0648},{"period":"6month","weight":0.1209},{"period":"1year","weight":0.4858},{"period":"ytd","weight":0.0707}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"397246人(较上一季度增加8.94%)","perCapita":"16058股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":"　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}